Vision Loss Clinical Trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.

The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase II Study to Assess the Safety Tolerability and Target Engagement of AMX0035 a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimers Disease

This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin Hizentra) in Adults with Dermatomyositis (DM)

This is a phase 3, 56-week, multicenter, randomized, placebo controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). Subjects will be randomized to 1 of 2 treatment sequences: Sequence A: 0.5 g/kg IgPro20 for 24 weeks followed by 0.5 g/kg IgPro20 for 28 weeks or …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease

Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects with Active Systemic Lupus Erythematosus (SLE) with Inadequate Response to Standard of Care (SOC) Therapy

The modification revised some of the risks. Initial submission. This is a double-blind, randomized, placebo-controlled, multicenter, phase 2 dose-ranging study to evaluate the efficacy and safety of AMG 570 in subjects with active SLE who are not responding to standard of care.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2 Randomized Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment period and an off-treatment follow-up period.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Giant Cell Arteritis

The main purpose of this study is to understand how well giant cell arteritis (also known as temporal arteritis; GCA) responds to an investigational drug called sarilumab. Sarilumab needs to be tested to find out if it is safe and effective in treating GCA. An investigational drug is one that …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 3 Double-Blind Randomized Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

  • 0 views
  • 19 Feb, 2024
  • 1 location
The OVAL Study: A Randomized Controlled Double-Arm Double-Blind Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

This double-blind, randomized controlled trial will examine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location